{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:29:41Z","timestamp":1747182581414,"version":"3.40.5"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672280"],"award-info":[{"award-number":["81672280"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016803","name":"Natural Science Foundation of Suzhou Municipality","doi-asserted-by":"publisher","award":["SYS2021042"],"award-info":[{"award-number":["SYS2021042"]}],"id":[{"id":"10.13039\/100016803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Whether the value of PD\u2010L1 expression from metastatic sites to predict the efficacy of immune checkpoint blockade (ICB)\u2010based treatment is equivalent to that from a primary tumor is uncertain. This study aimed to compare the utility of PD\u2010L1 TPS from a primary lung tumor and metastatic sites to predict the overall response rate (ORR) of first\u2010line ICB\u2010based treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included 249 patients with advanced non\u2010small cell lung cancer (NSCLC) who received first\u2010line ICB\u2010based treatment. All subjects underwent PD\u2010L1 testing prior to ICB\u2010based treatment and were divided into two cohorts corresponding to the different biopsy sites: lung primary site\u2010sampled cohort (PT cohort, <jats:italic>n<\/jats:italic>\u2009=\u2009167) and metastatic site\u2010sampled cohort (MT cohort, <jats:italic>n<\/jats:italic>\u2009=\u200982).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no statistical significance in PD\u2010L1 TPS distribution between the two cohorts (<jats:italic>p<\/jats:italic>\u2009=\u20090.742). PD\u2010L1 TPS \u226550% was also related to high ORR compared with PD\u2010L1\u2009&lt;\u200950% in the PT cohort (34.3% vs. 14.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). In contrast, ICB\u2010based therapy could bring comparable ORR (35.1% vs. 33.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.871) in the MT cohort regardless of PD\u2010L1 TPS status (\u226550%, or\u2009&lt;50%). As supported, when the cutoff value of TPS was selected as 50%, it was suggested that PT\u2010related PD\u2010L1 was the independent predictor of ORR (OR 2.870, 95% CI: 1.231\u20136.694, <jats:italic>p<\/jats:italic>\u2009=\u20090.015) rather than MT\u2010related PD\u2010L1 (OR 0.689, 95% CI: 0.236\u20132.013, <jats:italic>p<\/jats:italic>\u2009=\u20090.495). Furthermore, ROC proved that PT\u2010related PD\u2010L1 expression manifested a better AUC of 0.621 (<jats:italic>p<\/jats:italic>\u2009=\u20090.026) than that of MT\u2010related PD\u2010L1 (AUC\u2009=\u20090.565, <jats:italic>p<\/jats:italic>\u2009=\u20090.362).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared with PT\u2010related PD\u2010L1 expression, MT\u2010related PD\u2010L1 expression showed limited value in predicting ORR in patients with advanced NSCLC receiving ICB\u2010based therapy. It was concluded that even patients with low MT\u2010related PD\u2010L1 expression could benefit from ICB\u2010based therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15201","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T05:29:27Z","timestamp":1703827767000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of primary and metastatic site\u2010related <scp>PD\u2010L1<\/scp> expression in predicting <scp>ORR<\/scp> in patients with advanced <scp>NSCLC<\/scp> who received <scp>ICB<\/scp>\u2010based therapy"],"prefix":"10.1111","volume":"15","author":[{"given":"Danhong","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Medicine The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-7991","authenticated-orcid":false,"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.026"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.12.002"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.186"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.06.002"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0542-OA"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002217"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-1471"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.769124"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.053"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.017"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy041"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"issue":"4","key":"e_1_2_10_21_1","article-title":"Single or combined immune checkpoint inhibitors compared to first\u2010line platinum\u2010based chemotherapy with or without bevacizumab for people with advanced non\u2010small cell lung cancer","volume":"4","author":"Ferrara R","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T02:05:52Z","timestamp":1707876352000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/1759-7714.15201"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15201","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"2023-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}